Dietary Adjuncts for Improving Testosterone Levels in Hypogonadal Males
Open accessAbstract
An increasing number of men are being diagnosed with hypogonadism. While many benefit from testosterone supplementation therapy, others who do not meet the criteria for hormone supplementation have turned to dietary adjuncts as a way or gaining improvements in libido, energy, and physical performance. These oral adjunct medications include controlled substances such as androstenedione, androstenediol as well as other “over-the-counter” options like DHEA (dehydroepiandrosterone) and herbal remedies like Tribulus terrestris. This review will focus on the use of these adjunct medications in isolation, or in combination with testosterone supplementation therapy as well as the biochemical nature of the supplements, the results of scientific trials as well as the side effects that limit their use. At the end of this review, physicians will have an improved understanding of the popular testosterone adjuncts being used currently as well as the availability of these substances and how they are used.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
DHEA is a precursor to androstenedione and androstenediol and is a weak partial androgen receptor agonist.
“DHEA is a precursor to androstenedione and androstenediol (Figure 3) and is a weak partial androgen receptor agonist (30).”
From Non-testosterone management of male hypogonadism: an examination of the existing literature (2020) · cites this paper as [30]
Cites
Vigen, R. (2013) · JAMA · doi:10.1001/jama.2013.280386 · Cited by 1,003 · see citing works
Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men
Finkle, W. D., Greenland, S., Ridgeway, G. K., Adams, J. L., Frasco, M. A., Cook, M. B., Fraumeni, J. F., & Hoover, R. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085805 · Cited by 735 · see citing works
Kupelian, V., Page, S. T., Araujo, A. B., Travison, T. G., Bremner, W. J., & McKinlay, J. B. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1326 · Cited by 561 · see citing works
Trends in androgen prescribing in the United States, 2001 to 2011
Baillargeon, J., Urban, R. J., Ottenbacher, K. J., Pierson, K. S., & Goodwin, J. S. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.6895 · Cited by 336 · see citing works
Oral Androstenedione Administration and Serum Testosterone Concentrations in Young Men
Leder, B. Z. (2000) · JAMA · doi:10.1001/jama.283.6.779 · Cited by 135 · see citing works
Corona, G., Rastrelli, G., Giagulli, V. A., Sila, A., Sforza, A., Forti, G., Mannucci, E., & Maggi, M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1358 · Cited by 105 · see citing works
Basu, R., Dalla Man, C., Campioni, M., Basu, A., Nair, K. S., Jensen, M. D., Khosla, S., Klee, G., Toffolo, G., Cobelli, C., et al. (2007) · Diabetes · doi:10.2337/db06-1504 · Cited by 63 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Non-testosterone management of male hypogonadism: an examination of the existing literature
Krzastek, S. C., & Smith, R. P. (2020) · Translational Andrology and Urology · doi:10.21037/tau.2019.11.16 · Cited by 34 · see citing works
“DHEA is a precursor to androstenedione and androstenediol (Figure 3) and is a weak partial androgen receptor agonist (30).”
BackgroundInfluential
- Authors
- Kovac, J. R., Pan, M., Arent, S., & Lipshultz, L. I.
- Affiliations
- Urology of Indiana (US)
- Baylor College of Medicine (US)
- Rutgers, The State University of New Jersey (US)
- Corresponding author
- Kovac, Jason R.
- Venue
- American Journal of Men's Health
- Publisher
- SAGE Publications
- Published
- 2016-07-07
- Volume
- 10
- Issue
- 6
- Pages
- NP109-NP117
- ISSN
- 1557-9883 (ISSN-L)
- 1557-9891
- OpenAlex
- W2324261850
- Cited by
- 18
- References
- 7
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 3 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 2 · 2016: 2
- FWCI
- 0.25
- Type
- journal article
- Language
- en
- Open access
- green
- doaj.org
- Locations
- American Journal of Men s Health (publishedVersion)
- PubMed (publishedVersion)
- Rutgers University Community Repository (Rutgers University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Reproductive Medicine › Sperm and Testicular Function
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- hypogonadism, androstenedione, androstenediol, dehydroepiandrosterone, Tribulus terrestris, herbal supplements, sexual desire, adverse effects, over-the-counter supplements
- MeSH terms
- Androstenedione, Dehydroepiandrosterone, Humans, Hypogonadism, Male, Quality of Life, Testosterone, Time Factors, Androstenediol, Dietary Supplements, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
